Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, February 24, 2022
[ Thu, Feb 24th 2022
] - WOPRAI
Wed, February 23, 2022
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
[ Wed, Feb 23rd 2022
] - WOPRAI
Lawrence Biegelsen Maintained (TNDM) at Buy with Increased Target to $166 on, Feb 23rd, 2022
Lawrence Biegelsen of Wells Fargo, Maintained "Tandem Diabetes Care, Inc." (TNDM) at Buy with Increased Target from $160 to $166 on, Feb 23rd, 2022.
Lawrence has made no other calls on TNDM in the last 4 months.
There is 1 other peer that has a rating on TNDM. Out of the 1 peers that are also analyzing TNDM, 0 agree with Lawrence's Rating of Hold.
This is the rating of the analyst that currently disagrees with Lawrence
- Jayson Bedford of "Raymond James" Maintained at Buy with Increased Target to $138 on, Thursday, November 4th, 2021
